ESI-08

• Description :

  ESI-08 is a potent and selective EPAC antagonist, which can completely inhibit both EPAC1 and EPAC2 (IC50 of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced EPAC activation, but does not inhibit cAMP-mediated PKA activation[1].

• CAS Number :

  [301177-43-5]

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  Ras

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; MAPK/ERK Pathway

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Cancer; Metabolic Disease; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/esi-08.html

• Purity :

  98.74

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  N#CC1=C(C2CCCCC2)N=C(SCC3=CC(C)=CC=C3C)NC1=O

• Molecular Formula :

  C20H23N3OS

• Molecular Weight :

  353.48

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Chen H, et al. 5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP. Bioorg Med Chem Lett. 2012 Jun 15;22 (12) :4038-43.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported